NCT05770102: DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
- State
- Under way
- Phase
- Phase 2 and Phase 3
- People
- 30 planned
- Started
- 25 Oct 2023
- Primary completion
- Oct 2029
- Arms
- Treatment Arm 02: Atezolizumab
- Results
- None posted
- 15 Mar 2023: Trial registered
- 25 Oct 2023: Trial started